Efavirenz is effective and its side effects are the reason newer drugs replaced it. They are concentrated in the central nervous system and they are experienced very differently between individuals.
What are the neuropsychiatric effects?
Vivid or disturbing dreams, dizziness, light-headedness, difficulty concentrating, a sense of detachment or unreality, insomnia and altered mood. These affect a large proportion of people to some degree in the first weeks.
Do they settle?
For many people, substantially, over two to four weeks. For a meaningful minority they persist, and persistence beyond a month or two is a reasonable point to conclude the drug does not suit you.
What about mood specifically?
Depression and anxiety are reported, and pooled trial analysis identified a higher rate of suicidality on efavirenz than on comparators. This is the most serious concern with the drug and it warrants prompt attention rather than waiting.
What should you do if mood changes?
Contact your clinic promptly. Do not attribute it to circumstances without mentioning the timing. Switching resolves it in most cases, and alternatives are readily available, so there is no reason to persist with this particular effect.
Who is worst affected?
Partly genetic. Common variants in the enzyme that clears efavirenz mean some people reach much higher levels at the same dose and suffer correspondingly more. People with existing mental health difficulties are also at greater risk.
What about rash?
Common in the first weeks, usually mild and self-limiting. Any rash with fever, blistering, peeling skin, or involvement of the mouth, eyes or genitals is an emergency and needs immediate attention rather than a call in the morning.
What about cholesterol?
Efavirenz raises cholesterol and triglycerides consistently, which contributes to cardiovascular risk over years. For someone who has been on it a long time, this is one of the stronger arguments for reviewing the regimen.
What about the liver?
Liver enzyme rises occur and are monitored, more commonly in people with hepatitis B or C. Yellowing of the eyes or skin, dark urine or pain under the right ribs warrant prompt contact.
What about breast tissue?
Gynaecomastia, an increase in breast tissue, has been reported with efavirenz. It is uncommon, can be distressing, and is worth raising since it is a recognised effect rather than something unrelated.
What about vitamin D?
Efavirenz lowers vitamin D levels through enzyme induction. The clinical significance is modest and supplementation is sometimes suggested, particularly where bone health is already a concern.
Can it affect drug tests?
Yes, and this catches people out. Efavirenz can produce false-positive results on some urine screening tests for cannabis and benzodiazepines. If you are subject to workplace testing, this is worth knowing and worth being able to explain.
Does the reduced dose help?
Evidence suggests fewer side effects at 400mg with comparable effectiveness. Where switching drug is difficult, asking about the reduced dose is a reasonable alternative to ask about.
What monitoring is there?
Blood tests every three to six months covering viral load, liver function and lipids. Mood is not monitored by any test, which is why reporting it yourself matters.
Is it worth switching if you are fine on it?
Not urgently. Plenty of people have taken efavirenz for years without difficulty. The lipid effect is the main reason a clinician might raise it, and that is a discussion rather than a necessity.
Should you look side effects up online?
The leaflet lists everything ever reported, which is alarming and unhelpful for judging likelihood. A clinic pharmacist will tell you which effects are common and which matter, in about two minutes.
What is worth recording?
When something started, how long it lasts, and whether anything else changed at the same time. A short note is considerably more useful at an appointment than trying to reconstruct whether a symptom followed starting efavirenz or something else.
Are side effects a reason to stop?
Not to stop, and often a reason to change. Stopping leaves you untreated; switching keeps you covered. Nearly every effect described here has an alternative regimen that avoids it, so the conversation is worth having.
Do experiences differ between people?
Substantially. Two people on identical regimens can have completely different experiences, which is why general descriptions only go so far. Your own first month is more informative than any list of possibilities.